Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT03074825Phase 1Terminated
- Sponsor
- Akeso, Inc.
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chiauranib in non-Hodgkin lymphoma (NHL), sponsored by Akeso, Inc. Primary endpoint: Overall Response Rate at 2 years. Started May 2017; status: terminated.
02
Drugs
chiauranib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03074825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074825.